

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Medigard Ltd

ABN

49 090 003 044

Quarter ended ("current quarter")

31 March 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (..9.....months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	12	19
1.2 Payments for		
(a) research and development	-	(128)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	(21)	(83)
(f) administration and corporate costs	(41)	(121)
1.3 Dividends received (see note 3)		
- Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
GST refund	22	22
Patent costs	(58)	(91)
Intellectual property licence fees	(25)	(60)
1.9 Net cash from / (used in) operating activities	(111)	(442)

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (..9.....months) \$A'000
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(2)
3.5 Proceeds from borrowings	95	95
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	95	93

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (..9.....months) \$A'000
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	44	377
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(111)	(442)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		
4.4 Net cash from / (used in) financing activities (item 3.10 above)	95	93
4.5 Effect of movement in exchange rates on cash held		
4.6 Cash and cash equivalents at end of quarter	28	28

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	28	44
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	28	44

Note 1: \$95,000 in loans from Directors was received 31 January 2019.

6. Payments to directors of the entity and their associates

6.1 Aggregate amount of payments to these parties included in item 1.2

**Current quarter
\$A'000**

(11)

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Director's PAYG tax and superannuation on prior quarters' salary paid to I E Dixon

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	854	854
8.2 Credit standby arrangements	-	-
8.3 Other (please specify) (Refer Note 1 above)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

All loans are unsecured.

- \$100,000 loan from D J Channer – 7.5% interest capitalised monthly. No repayment date.
- \$100,000 loan from Vestcare Pty Ltd – 7.5% interest capitalised monthly. No repayment date.
- \$95,000 loans from Directors 7.5% interest capitalised monthly. No repayment date.
- \$127,360 convertible notes held by Sol Millennium Medical HK Ltd – 8% interest capitalised monthly, currently repayable 30 June 2019 and subject to renegotiation, refer announcement 30 April 2019
- \$205,756 convertible notes held by Sol Millennium Medical HK Ltd – 8% interest capitalised monthly, currently repayable 30 June 2019 and subject to renegotiation, refer announcement 30 April 2019
- \$225,992 convertible notes held by Sol Millennium Medical HK Ltd – 8% interest capitalised quarterly, currently repayable 30 June 2019 and subject to renegotiation, refer announcement 30 April 2019

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	
9.2 Product manufacturing and operating costs	
9.3 Advertising and marketing	
9.4 Leased assets	
9.5 Staff costs	(12)
9.6 Administration and corporate costs (incl. insurance)	(40)
9.7 Other (provide details if material)	
Patent costs	(2)
IP Licencing	-
9.8 Total estimated cash outflows	(54)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Company secretary)

Date: ..30 April 2019

Print name: PATRICIA BOERO.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.